Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female subjects between the ages of \>=11 and \<=18 years at the time of enrollment.~* Negative urine pregnancy test for all female subjects.~* Parent/legal guardian or subject under supervision of the parent/legal guardian must be able to complete all relevant study procedures during study participation.~Exclusion Criteria:~* History of any invasive meningococcal disease.~* A previous anaphylactic or severe vaccine-associated adverse reaction.~* Any clinically significant chronic disease.~* A known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids. Topical, inhaled or intra-articular corticosteroids are allowed.~* Participation in another investigational study in the 1-month (30-day) period before study visit 1 and during the conduct of the study.

- Gender: ALL
- Minimum Age: 11 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): dose level 1 rLP2086 vaccine
- 2 (Type: EXPERIMENTAL): dose level 2 rLP2086 vaccine
- 3 (Type: EXPERIMENTAL): dose level 3 rLP2086 vaccine
- 4 (Type: PLACEBO_COMPARATOR): normal saline (placebo)

Based on this trial design, predict the completion outcome and termination type (if applicable).